Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL
Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.
Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.
Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.
SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.
Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.
Study results suggest that capecitabine should be incorporated into standard care for biliary tract cancer.
The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.
Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.